Participated · Series A · Jun 2024

Canary Speech develops an API-first vocal biomarker platform that captures and analyzes speech data within seconds using patented real-time vocal analysis. Its technology is designed to screen for invisible illnesses such as anxiety, depression, and dementia by identifying behavioral and cognitive irregularities before current clinical screening standards or noticeable symptoms. The company offers applications across healthcare including contact centers, ambient clinical listening, remote patient monitoring, and annual wellness checks. Ambient listening tools are positioned to unobtrusively capture and analyze conversations in real time while documenting clinical notes. Led by CEO Henry O’Connell and based in Provo, UT, Canary emphasizes integrations that support provider workflows. The company intends to use recent funding to expand its team to support growth driven by AI advancements and healthcare demand for advanced tools.